Amgen Slumps on Safety Concerns for Experimental Obesity Drug

Amgen (AMGN) shares have taken a sharp downturn after Cantor Fitzgerald raised concerns about safety data for its experimental obesity drug, MariTide. Initial trial results showed that some patients experienced a loss of bone mineral density, which could potentially weaken the medication's competitiveness against Eli Lilly and Novo Nordisk's top-selling treatments.

This development has overshadowed the broader market environment and turned MariTide from a promising growth driver to an immediate concern for the stock. The selloff is driven by worries that safety questions may slow down development, complicate regulatory approval, or force costly changes to trial design and marketing strategy.

Despite today's decline, Amgen's strong free cash flow provides it with sufficient resources to continue funding research, manufacturing expansion, dividends, and buybacks even if one program encounters setbacks. This financial cushion can help the company navigate challenges and maintain its investment in promising drugs across its diverse portfolio.